View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Gran Tierra Energy Inc. Announces 2026 Guidance and Operations Update

Gran Tierra Energy Inc. Announces 2026 Guidance and Operations Update Targeting Free Cash Flow of $60 to $80 Million in the 2026 Base CaseEcuador Program Transition From Exploration to Appraisal & Development Colombia Program Focused on Maximizing Free Cash Flow Development Program Focused on Quick Payouts and Capital Efficient Projects2026 Capital Program Fulfills Commitments Over the Suroriente Block Reported Current Company Production of 48,000 to 49,000 BOEPD CALGARY, Alberta, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GT...

Gran Tierra Energy Inc.: Update following placement of ratings under r...

Our credit view of this issuer reflects its event risk from future acquisitions and its small production and reserve size.

Salesforce Inc: 1 director

A director at Salesforce Inc sold 33 shares at 0.000USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

 PRESS RELEASE

Ernexa Therapeutics Presents New Preclinical Data at American Society ...

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad oncology applications, including hematologic malignancies CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentat...

Moody's Ratings places Gran Tierra under review for downgrade

Moody's Ratings (Moody's) has placed Gran Tierra Energy Inc.'s ("Gran Tierra") Corporate Family Rating and senior secured notes B2 ratings under review for downgrade. Previously, the outlook was positive. RATINGS RATIONALE / FACTORS THAT COULD LEAD TO AN UPGRADE OR DOWNGRADE OF THE RATINGS The r...

 PRESS RELEASE

Victoria’s Secret & Co. Reports Third Quarter 2025 Results and Raises ...

Victoria’s Secret & Co. Reports Third Quarter 2025 Results and Raises Full Year Guidance Delivered Net Sales of $1.472 Billion, a 9% Increase Versus Prior Year, Exceeding ExpectationsOperating Results and Earnings Exceed ExpectationsRaises Fiscal Year 2025 Net Sales, Operating Income and Earnings Guidance REYNOLDSBURG, Ohio, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSCO) today reported financial results for the third quarter ended November 1, 2025. Hillary Super, VS&Co Chief Executive Officer, said, “We delivered a standout third quarte...

Anish Jog ... (+6)
  • Anish Jog
  • Daniel Ives
  • Matthew Weiss
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig

Good Results with 4Q Revenue Above Street; Need to Continue on Path Fo...

A Closer Look at FY3Q26 (October) ResultsRevenueTotal revenue of $10.26 billion (up 9% y/y and 8% y/y in CC) was in line with both the company’s guidance range for revenue between $10.24 billion and $10.29 billion and the Street’s $10.27 billion estimate driven by Agentforce, Data 360, and Agentfor

 PRESS RELEASE

Ernexa Therapeutics Announces Oral Presentation at the 67th American S...

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the , being held December 6-9, 2025 in Orlando, FL. “Being selected to give an oral presentation at ASH is a tremendous honor and a major milestone,” said Sanjeev Luther, President & CEO of Ern...

 PRESS RELEASE

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board ...

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trials CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its . Dr. Winer is a nationally recogni...

David Nierengarten ... (+9)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch